< Back to previous page
Researcher
Johan Vansteenkiste
- Disciplines:Respiratory medicine
Affiliations
- Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) (Division)
Member
From1 Oct 1999 → 30 Sep 2022
Projects
1 - 3 of 3
- Refining the role of dual checkpoint inhibition in advanced lung cancer: a single-cell approachFrom5 Oct 2021 → TodayFunding: FWO Strategic Basic Research Grant
- A single-cell approach to identify biomarkers of efficacy and toxicity for immune checkpoint blockade in non-small cell lung cancer.From1 Aug 2019 → 1 Aug 2023Funding: FWO Strategic Basic Research Grant, Foundations, funds and other with scientific goal
- Unraveling the common genetic basis for COPD, emphysema and lung cancer.From1 Aug 2010 → 16 Dec 2015Funding: Private funding of national origin - undefined, FWO fellowships
Publications
1 - 10 of 249
- Atypical presentation of leptomeningeal disease in lung adenocarcinoma: the bloomy rind sign(2025)Published in: Acta Neurologica BelgicaISSN: 0300-9009Issue: 4Volume: 125Pages: 1135 - 1137
- Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial(2024)Published in: The Lancet OncologyISSN: 1470-2045Issue: 10Volume: 25Pages: 1357 - 1370
- Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC(2024)Published in: JTO Clin Res RepISSN: 2666-3643Issue: 3Volume: 5
- Single-cell phenotyping to unravel the immunopathology of immune checkpoint inhibitor-related pneumonitis. Lessons learnt from the COVID-19 pandemic(2023)
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer (Reprinted from vol 26, pg 3543-3551, 2008)(2023)Published in: JOURNAL OF CLINICAL ONCOLOGYISSN: 0732-183XIssue: 14Volume: 41Pages: 2458 - 2466
- Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors(2023)Published in: EUROPEAN JOURNAL OF CANCERISSN: 0959-8049Volume: 183Pages: 142 - 151
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer (Reprinted from vol 21, pg 2237-2246, 2003)(2023)Published in: JOURNAL OF CLINICAL ONCOLOGYISSN: 0732-183XIssue: 6Volume: 41Pages: 1162 - 1171
- Treatment of unresectable stage III NSCLC: Real world cohort study and literature review(2023)Published in: Cancer Treat Res CommunISSN: 2468-2942Volume: 36
- A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data(2023)Published in: Future OncologyISSN: 1479-6694Issue: 1Volume: 19Pages: 61 - 75
- Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis(2022)Published in: Journal for ImmunoTherapy of CancerISSN: 2051-1426Issue: 9Volume: 10